Anna Fedorova talks to the head of Polar Capital's healthcare franchise, Daniel Mahony, about biotech, ageing populations, and whether the M&A boom in the pharmaceutical space is already over.
Polar Capital's Daniel Mahony has a detailed knowledge of the healthcare industry, having worked for a biotech company in the 1990s before moving over to the investment industry in 1998. Like other top managers in the space, Mahony is a former scientist who made the decision to carve out a niche in fund management. He set up the first healthcare fund at Polar Capital in 2007 with Gareth Powell, who was running the Framlington Biotech fund at the time. The meeting of minds has produced impressive results for investors. Since launch, the duo have stood out in a sector which has signi...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes